CoChat

Homocysteine‐lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease

Open access
Bleie, Ø., Semb, A. G., Grundt, H., Nordrehaug, J. E., Vollset, S. E., Ueland, P. M., Nilsen, D. W. T., Bakken, A. M., Refsum, H., Nygård, O. K. · 2007 · Journal of Internal Medicine
Cited by 57

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

: Objectives. A high level of total homocysteine (tHcy) is a risk marker for cardiovascular disease (CVD), and is related to inflammation. We wanted to test the effect of homocysteine‐lowering B‐vitamin therapy, as used in the Western Norway B‐vitamin Intervention Trial (WENBIT), on inflammatory markers associated with atherosclerosis. Design. Single centre, prospective double‐blind clinical interventional study, randomised in a 2 × 2 factorial design. Subjects and methods. Ninety patients (21 female) with suspected coronary artery disease (CAD), aged 38–80 years, were blindly randomised into one of four groups of daily oral treatment with (A) folic acid (0.8 mg)/vitamin B12 (0.4 mg)/vitamin B6 (40 mg), (B) folic acid/vitamin B12, (C) vitamin B6 alone or (D) placebo. Blood samples were collected before and after 6 months of treatment. Results. Before intervention, median levels of the analytes were: tHcy 11.0 μ mol L−1, neopterin 8.1 nmol L−1, soluble CD40 ligand (sCD40L) 3.9 ng mL−1, interleukin (IL)‐6 1.9 pg mL−1, C‐reactive protein (CRP) 1.9 mg L−1 and low‐density lipoprotein (LDL) cholesterol 3.3 mmol L−1. tHcy was significantly associated with neopterin (r = 0.49, P < 0.001) and with IL‐6 (r = 0.29, P = 0.01), but not with CRP or sCD40L. Neither treatment with folic acid/B12 nor with B6 induced significant changes in any of these inflammatory biomarkers (P ≥ 0.14). In patients receiving folic acid/B12 (groups A and B), tHcy was reduced with 33% (P < 0.001). Conclusions. In patients with stable CAD, homocysteine‐lowering therapy with B‐vitamins does not affect levels of inflammatory markers associated with atherogenesis. Failure to reverse inflammatory processes, may partly explain the negative results in clinical secondary B‐vitamin intervention trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2796.2007.01810.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 57

Metadata

Authors
Bleie, Ø., Semb, A. G., Grundt, H., Nordrehaug, J. E., Vollset, S. E., Ueland, P. M., Nilsen, D. W. T., Bakken, A. M., Refsum, H., & Nygård, O. K.
Venue
Journal of Internal Medicine
Publisher
Wiley
Published
2007-04-13
Volume
262
Issue
2
Pages
244-253
ISSN
  • 0954-6820 (ISSN-L)
  • 1365-2796
OpenAlex
W2142964752
Cited by
57
References
5
FWCI
3.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Homocysteine‐lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. https://app.cochat.ai/papers/10.1111/j.1365-2796.2007.01810.x
The paper
Bleie, Ø., Semb, A. G., Grundt, H., Nordrehaug, J. E., Vollset, S. E., Ueland, P. M., Nilsen, D. W. T., Bakken, A. M., Refsum, H., & Nygård, O. K. (2007). Homocysteine‐lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.2007.01810.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.